Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD; Anne L. Peters, MD

May 16, 2022

Both DPP-4 inhibitors and GLP-1 RAs are effective at lowering hemoglobin A1c levels. Incretin-based therapies have a low incidence of hypoglycemia and are safe to use in patients with chronic kidney disease. In addition, studies have suggested that DDP-4 inhibitors may reduce albuminuria and improve various renal inflammatory markers. However, GLP-1 RAs and sodium-glucose cotransporter 2 (SGLT2) inhibitors more effectively lower glycemia compared with DPP-4 inhibitors.

GLP-1 RAs have been shown to lower all-cause mortality and nonfatal cardiovascular complications. Although DDP-4 inhibitors may be safe to use in patients with heart failure, they are not effective in reducing cardiovascular outcomes.

Learn more about type 2 diabetes.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Romesh Khardori, Anne L. Peters. Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy - Medscape - May 16, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Need a Curbside Consult? Share cases and questions with Physicians on Medscape Consult. Share a Case

Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

Romesh Khardori, MD, PhD

Anne L. Peters, MD

Comments

Email This

Feedback